according to the Hazardous Products Regulations



Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/26/2023
7.2	04/06/2024	24354-00023	Date of first issue: 10/21/2014

SECTION 1. IDENTIFICATION

Product name	:	Simvastatin Formulation
Other means of identification	:	No data available

Manufacturer or supplier's details

Company name of supplier	:	Organon & Co.
Address	:	30 Hudson Street, 33nd floor
		Jersey City, New Jersey, U.S.A 07302
Telephone	:	1-551-430-6000
Emergency telephone	:	1-215-631-6999
E-mail address	:	EHSSTEWARD@organon.com
	_	

Recommended use of the chemical and restrictions on use

Recommended use	: Pharmaceutical
Restrictions on use	: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations Skin sensitization : Category 1					
Carcinogenicity (Inhalation)	:	Category 2			
Specific target organ toxicity - repeated exposure	:	Category 1 (Liver, muscle, optic nerve, Eye)			
GHS label elements Hazard pictograms	:				
Signal Word	:	Danger			
Hazard Statements	:	H317 May cause an allergic skin reaction. H351 Suspected of causing cancer if inhaled. H372 Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.			
Precautionary Statements	:	 Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P272 Contaminated work clothing should not be allowed out of the workplace. 			

according to the Hazardous Products Regulations



Simvastatin Formulation

Version 7.2	Revision Date: 04/06/2024	SDS Number: 24354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014
		P280 Wear pr and face prote	otective gloves, protective clothing, eye protection ection.
		P308 + P313 P333 + P313 tion.	IF ON SKIN: Wash with plenty of water. IF exposed or concerned: Get medical attention. If skin irritation or rash occurs: Get medical atten- Take off contaminated clothing and wash it before
		Storage: P405 Store lo	cked up.
		Disposal: P501 Dispose disposal plant	of contents and container to an approved waste
Othe	r hazards		

Other hazards

Dust contact with the eyes can lead to mechanical irritation. May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Simvastatin	No data availa- ble	79902-63-9	>= 5 - < 10 *
Starch	Sago starch	9005-25-8	>= 5 - < 10 *
Cellulose	No data availa- ble	9004-34-6	>= 1 - < 5 *
Ascorbic acid	No data availa- ble	50-81-7	>= 1 - < 5 *
Citric acid monohy- drate	2- hydroxypro- pane-1,2,3- tricarboxylic acid hydrate	5949-29-1	>= 1 - < 5 *
Titanium dioxide	Titanic anhy- dride	13463-67-7	>= 0.1 - < 1 *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice	 In the case of accident or if you feel unwell, seek medical advice immediately.
	When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.

according to the Hazardous Products Regulations



Simvastatin Formulation

Version 7.2	Revision Date: 04/06/2024	SDS Number: 24354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014			
In case of skin contact		 In case of contact, immediately flush skin with plenty of wa Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. 				
In cas	se of eye contact	: If in eyes, rinse	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.			
lf swa	llowed	: If swallowed, I Get medical at	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.			
	important symptoms ffects, both acute and ed	: May cause an Suspected of c Causes damag exposure.	 May cause an allergic skin reaction. Suspected of causing cancer if inhaled. Causes damage to organs through prolonged or repeated exposure. Dust contact with the eyes can lead to mechanical irritation. 			
Prote	ction of first-aiders	: First Aid respo and use the re	nders should pay attention to self-protection, commended personal protective equipment ntial for exposure exists (see section 8).			
Notes	to physician	: Treat symptom	natically and supportively.			

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

according to the Hazardous Products Regulations



Simvastatin Formulation

Version 7.2	Revision Date: 04/06/2024	SDS Number: 24354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014
		Local authoriti cannot be con	es should be advised if significant spillages tained.
	ds and materials for nment and cleaning up	container for d Avoid dispersa with compress Dust deposits surfaces, as th released into t Local or natior disposal of this employed in th determine whi Sections 13 ar	al of dust in the air (i.e., clearing dust surfaces

SECTION 7. HANDLING AND STORAGE

Technical measures	 Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation Advice on safe handling	 Use only with adequate ventilation. Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage	 Keep in properly labeled containers. Store in accordance with the particular national regulations.
Materials to avoid	 Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

according to the Hazardous Products Regulations



Simvastatin Formulation

sion	Revision Date: 04/06/2024	SDS Number: 24354-00023		t issue: 09/26/2023 t issue: 10/21/2014	
Comp	onents	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Simva	statin	79902-63-9	TŴA	25 µg/m3 (OEB 3)	Internal
		Further inform		<u> </u>	
			Wipe limit	250 µg/100 cm ²	Internal
Starch	า	9005-25-8	TŴA	10 mg/m ³	CA AB OE
			TWA (Total dust)	10 mg/m ³	CA BC OE
			TWA (respir- able dust fraction)	3 mg/m³	CA BC OE
			TWAEV (to- tal dust)	10 mg/m³	CA QC OE
			TWA	10 mg/m ³	ACGIH
Cellul	ose	9004-34-6	TWA	10 mg/m ³	CA AB OE
			TWA (Total dust)	10 mg/m³	CA BC OE
			TWA (respir- able dust fraction)	3 mg/m ³	CA BC OE
			TWAEV (to- tal dust)	10 mg/m ³	CA QC OE
			TWA	10 mg/m ³	ACGIH
Ascor	bic acid	50-81-7	TWA	5000 µg/m3 (OEB 1)	Internal
Titaniu	um dioxide	13463-67-7	TWA	10 mg/m ³	CA AB OE
			TWA (Total dust)	10 mg/m ³	CA BC OE
			TWA (respir- able dust fraction)	3 mg/m ³	CA BC OE
			TWAEV (to- tal dust)	10 mg/m ³	CA QC OE

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection Filter type Hand protection		If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Particulates type
Material	:	Chemical-resistant gloves

according to the Hazardous Products Regulations



Simvastatin Formulation

Version 7.2	Revision Date: 04/06/2024	SDS Number: 24354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014
	emarks rotection	If the work envi mists or aeroso Wear a faceshi potential for dire	e gloving. Isses with side shields or goggles. ronment or activity involves dusty conditions, Is, wear the appropriate goggles. eld or other full face protection if there is a ect contact to the face with dusts, mists, or
Skin and body protection		Additional body task being perfo disposable suits	r laboratory coat. garments should be used based upon the prmed (e.g., sleevelets, apron, gauntlets, s) to avoid exposed skin surfaces. e degowning techniques to remove potentially lothing.
Hygiene measures		: If exposure to c eye flushing sys working place. When using do Contaminated v workplace. Wash contamin The effective op engineering cor appropriate deg	hemical is likely during typical use, provide stems and safety showers close to the not eat, drink or smoke. vork clothing should not be allowed out of the ated clothing before re-use. beration of a facility should include review of ntrols, proper personal protective equipment, gowning and decontamination procedures, ne monitoring, medical surveillance and the

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder	
Color	:	No data available	
Odor	:	odorless	
Odor Threshold	:	No data available	
рН	:	No data available	
Melting point/freezing point	:	No data available	
Initial boiling point and boiling range	:	No data available	
Flash point	:	Not applicable	
Evaporation rate	:	Not applicable	
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.	
Flammability (liquids)	:	No data available	
Upper explosion limit / Upper	:	No data available	

according to the Hazardous Products Regulations



Simvastatin Formulation

Vers 7.2	sion	Revision Date: 04/06/2024		S Number: 354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014
	flamma	ability limit			
		explosion limit / Lower ability limit	:	No data available	
	Vapor p	oressure	:	Not applicable	
	Relativ	e vapor density	:	Not applicable	
	Relativ	e density	:	No data available)
	Density	/	:	No data available	
	Solubili Wat	ity(ies) ter solubility	:	No data available)
	Partitio octanol	n coefficient: n-	:	Not applicable	
		nition temperature	:	No data available	
	Decom	position temperature	:	No data available)
	Viscosi Visc	ty cosity, kinematic	:	Not applicable	
	Explosi	ive properties	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Particle Particle	e characteristics e size	:	No data available	9

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions		Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

according to the Hazardous Products Regulations



/ersion 7.2	Revision Date: 04/06/2024	SDS Number: 24354-00023		Date of last issue: 09/26/2023 Date of first issue: 10/21/2014	
ECTION	11. TOXICOLOGICA		ORMATION		
Infor	mation on likely rout	es of	exposure		
Inhala Skin Inges	ation contact				
	e toxicity				
	lassified based on available	ailable	information.		
	ponents:				
-	a statin: e oral toxicity	:	LD50 (Rat): 5,	000 mg/kg	
			LD50 (Mouse)	: 3,800 mg/kg	
Starc	:h:				
Acute	e oral toxicity	:	LD50 (Rat): > :	5,000 mg/kg	
Acute	e dermal toxicity	:	LD50 (Rabbit):	> 2,000 mg/kg	
Cellu	llose:				
Acute	e oral toxicity	:	LD50 (Rat): >	5,000 mg/kg	
Acute	e inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist		
Acute	e dermal toxicity	:	LD50 (Rabbit):	> 2,000 mg/kg	
Asco	orbic acid:				
Acute	e oral toxicity	:	LD50 (Rat): 11	,900 mg/kg	
Citric	c acid monohydrate:				
Acute	e oral toxicity	:	LD50 (Mouse)	5,400 mg/kg	
Acute	e dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity		
Titan	ium dioxide:				
Acute	e oral toxicity	:	LD50 (Rat): > 5	5,000 mg/kg	
Acute	e inhalation toxicity	:	LC50 (Rat): > Exposure time Test atmosphe Assessment: T	: 4 h	

according to the Hazardous Products Regulations



ersion 2	Revision Date: 04/06/2024		S Number: 354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014
			tion toxicity	
Skin (corrosion/irritation			
Not cl	assified based on ava	ailable	information.	
<u>Comr</u>	oonents:			
Simva	astatin:			
Speci Rema		:	Rabbit Moderate skin	irritation
Asco	rbic acid:			
Speci		:	Rabbit	
Metho		:	OECD Test Gu	
Resul	t	:	No skin irritatio	m
Citric	acid monohydrate:			
Speci		:	Rabbit	
Resul	t	:	No skin irritatio	on
Titani	um dioxide:			
Specie Resul		irritatio	Rabbit No skin irritatic on	on
Resul Serio Not cl	t us eye damage/eye assified based on ava	: irritati	No skin irritatic on	n
Resul Serio Not cl <u>Comp</u>	t us eye damage/eye assified based on ava ponents:	: irritati	No skin irritatic on	n
Resul Serio Not cl <u>Comp</u> Simva	t us eye damage/eye assified based on ava ponents: astatin:	: irritati	No skin irritatio on information.	n
Resul Serio Not cl <u>Comp</u>	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es	: irritati	No skin irritatic on	n
Resul Serio Not cl <u>Comp</u> Simva Specie	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es	: irritati	No skin irritatio on information. Rabbit	ภ
Resul Serio Not cl Comp Simva Specia Rema	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es es rks	: irritati	No skin irritatio on information. Rabbit slight irritation	n
Resul Serio Not cl Comp Simva Specie Rema Starc Specie	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es rks h: es	: irritati	No skin irritatio on information. Rabbit slight irritation Rabbit	
Resul Serio Not cl Comp Simva Specia Rema	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es rks h: es	: irritati e ailable : :	No skin irritatio on information. Rabbit slight irritation	
Resul Serio Not cl Comp Simva Specia Rema Starc Specia Resul	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es rks h: es	: irritati e ailable : :	No skin irritatio on information. Rabbit slight irritation Rabbit	
Resul Serio Not cl Comp Simva Specia Rema Starc Resul Ascol Specia	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es rks h: es t t rbic acid: es	: irritati e ailable : :	No skin irritatio on information. Rabbit slight irritation Rabbit No eye irritatio Rabbit	n
Resul Serio Not cl Comp Simva Specia Rema Starcl Resul Ascon Specia Resul	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es rks h: es t t rbic acid: es t	: irritati e ailable : :	No skin irritatio on information. Rabbit slight irritation Rabbit No eye irritatio Rabbit No eye irritatio	n
Resul Serio Not cl Comp Simva Specia Rema Starc Resul Ascol Specia	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es rks h: es t t rbic acid: es t	: irritati e ailable : :	No skin irritatio on information. Rabbit slight irritation Rabbit No eye irritatio Rabbit	n
Resul Serio Not cl Comp Simva Specia Resul Ascor Specia Resul Metho	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es rks h: es t rbic acid: es t od acid monohydrate:	: irritatio ailable : : : : :	No skin irritatio on information. Rabbit slight irritation Rabbit No eye irritatio Rabbit No eye irritatio OECD Test Gu	n
Resul Serio Not cl Comp Simva Specie Resul Specie Resul Ascou Specie Resul Metho Citric Specie	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es rks h: es t rbic acid: es t acid monohydrate: es	: irritatio ailable : : : : :	No skin irritation on information. Rabbit slight irritation Rabbit No eye irritation Rabbit No eye irritatio OECD Test Gu Rabbit	n n uideline 405
Resul Serio Not cl Comp Simva Specia Resul Ascor Specia Resul Metho	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es rks h: es t rbic acid: es t acid monohydrate: es	: irritatio ailable : : : : :	No skin irritation on information. Rabbit slight irritation Rabbit No eye irritation Rabbit No eye irritatio OECD Test Gu Rabbit	n
Resul Serio Not cl Comp Simva Specia Rema Starcl Specia Resul Metho Citric Specia Resul	t us eye damage/eye assified based on ava <u>ponents:</u> astatin: es rks h: es t rbic acid: es t acid monohydrate: es	: irritatio ailable : : : : :	No skin irritation on information. Rabbit slight irritation Rabbit No eye irritation Rabbit No eye irritatio OECD Test Gu Rabbit	n n uideline 405

according to the Hazardous Products Regulations



ersion 2	Revision Date: 04/06/2024	SDS Number: 24354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014
Resul	lt	: No eye irritatior	n
Resp	iratory or skin sensi	tization	
Skin	sensitization		
May c	cause an allergic skin	reaction.	
Resp	iratory sensitization		
Not cl	lassified based on ava	ailable information.	
<u>Comp</u>	oonents:		
Simv	astatin:		
Asses	ssment	: Probability or e	vidence of skin sensitization in humans
Resul	lt	: positive	
Starc	h:		
Test		: Maximization T	est
Route	es of exposure	: Skin contact	
Speci Resul		: Guinea pig	
Resu	I	: negative	
Asco	rbic acid:		
Test 7		: Maurer optimis	ation test
Route Speci	es of exposure	: Skin contact : Guinea pig	
Resul		: negative	
Titan	ium dioxide:		
Test		: Local lymph no	de assay (LLNA)
Route	es of exposure	: Skin contact	,
Speci Resul		: Mouse	
Resul	it.	: negative	
	cell mutagenicity		
	lassified based on ava	ailable information.	
	oonents:		
	astatin:	-	
Geno	toxicity in vitro	: Test Type: Bac Result: negativ	eterial reverse mutation assay (AMES) e
		Test Type: Alka Result: negativ	aline elution assay e
		Test Type: Chr Result: negativ	omosomal aberration e
		Test Type: In v Result: negativ	itro mammalian cell gene mutation test e

according to the Hazardous Products Regulations



Version 7.2	Revision Date: 04/06/2024	SDS Number: 24354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014
Geno	toxicity in vivo	: Test Type: Mi Species: Mou Application R Result: negat	oute: Oral
	cell mutagenicity - ssment	: Weight of evid cell mutagen.	dence does not support classification as a germ
Starc Geno	h: toxicity in vitro	: Test Type: Ba Result: negat	acterial reverse mutation assay (AMES) ive
Cellu Geno	lose: toxicity in vitro	Result: negat	acterial reverse mutation assay (AMES) ive vitro mammalian cell gene mutation test
Geno	toxicity in vivo	Result: negat : Test Type: Ma cytogenetic a Species: Mou	ive ammalian erythrocyte micronucleus test (in vivo ssay) ise oute: Ingestion
	rbic acid: toxicity in vitro	Result: negat	vitro mammalian cell gene mutation test
Geno	toxicity in vivo	Result: negat : Test Type: Ma cytogenetic a Species: Mou	ammalian erythrocyte micronucleus test (in vivo ssay) Ise oute: Ingestion
	acid monohydrate: toxicity in vitro	Result: negat Test Type: in	vitro micronucleus test
		Result: positiv Test Type: Ba Result: negat	acterial reverse mutation assay (AMES)
		11/2	20

according to the Hazardous Products Regulations



ersion .2	Revision Date: 04/06/2024	SDS Number: 24354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014			
Geno	toxicity in vivo	cytogenetic te	itagenicity (in vivo mammalian bone-marrow st, chromosomal analysis)			
		Species: Rat Application Ro Result: negativ				
Titani	ium dioxide:					
Geno	toxicity in vitro	: Test Type: Ba Result: negativ	cterial reverse mutation assay (AMES) ve			
Geno	toxicity in vivo	: Test Type: In Species: Mous Result: negativ				
	nogenicity ected of causing canc	er if inhaled.				
Comp	oonents:					
Simva	astatin:					
Speci		: Mouse				
	cation Route	: Oral				
	sure time et Organs	: < 92 weeks : Harderian glar	bd			
	r Type	: Liver, Lungs				
Rema			ce of these findings for humans is not certair			
Speci	es	: Rat				
	cation Route	: Oral				
	sure time r Type	: 2 Years				
Rema			Liver, ThyroidThe significance of these findings for humans is not certain			
Cellu	lose:					
Speci	es	: Rat				
	cation Route	: Ingestion				
Expos Resul	sure time	: 72 weeks				
Resul	ι	: negative				
Asco	rbic acid:					
Speci		: Mouse				
	cation Route	: Ingestion				
Expos Resul	sure time t	: 2 Years : negative				
Titani	ium dioxide:					
		: Rat				
I		: inhalation (due	st/mist/fume)			
Exposure time						
		: 2 Years : OECD Test G				

according to the Hazardous Products Regulations



Version 7.2	n	Revision Date: 04/06/2024		9S Number: 354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014
	Result Remarks Carcinogenicity - Assess- ment		:	positive The mechanism o mans.	r mode of action may not be relevant in hu-
			:	Limited evidence animals.	of carcinogenicity in inhalation studies with
	-	luctive toxicity ssified based on availa	ble	information.	
<u>C</u> (ompo	onents:			
Si	imvas	statin:			
Ef	ffects	on fertility	:	Test Type: Fertility Species: Rat, mal Application Route Fertility: LOAEL: 2	e
Ef	ffects	on fetal development	:	Species: Rat Application Route Embryo-fetal toxic Result: No teratog Test Type: Embry Species: Rabbit Application Route Embryo-fetal toxic	ity.: NOAEL: 25 mg/kg body weight jenic effects., No adverse effects. o-fetal development
				Test Type: Embry Species: Rat Application Route Embryo-fetal toxic Result: Teratogen	o-fetal development : Oral ity.: LOAEL: 60 mg/kg body weight
C	ellulo	se:			
Ef	ffects	on fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion
Ef	ffects	on fetal development	:	Test Type: Fertility Species: Rat Application Route Result: negative	/early embryonic development
		ic acid: on fetal development	:	Test Type: Embry Species: Rat Application Route	o-fetal development : Ingestion

according to the Hazardous Products Regulations



/ersion 7.2	Revision Date: 04/06/2024	SDS Number: 24354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014
		Result: nega	ative
Citric	acid monohydrate:		
	s on fetal developmen	Species: Ra	Route: Ingestion
	-single exposure assified based on avai	lable information.	
Com	oonents:		
Citric	acid monohydrate:		
Asses	ssment	: May cause r	espiratory irritation.
	-repeated exposure es damage to organs (Liver, muscle, optic	c nerve, Eye) through prolonged or repeated expo-
Com	oonents:		
Simv	astatin:		
-	et Organs ssment		e, optic nerve, Eye hage to organs through prolonged or repeated
Repe	ated dose toxicity		
Com	oonents:		
Simv	astatin:		
Speci	es	: Rat	
NOAE		: 5 mg/kg	
LOAE		: 30 mg/kg	
	cation Route sure time	: Oral : 14 - 104 We	ocko
	et Organs		, Musculo-skeletal system, Eye
Speci	es	: Dog	
LOAE		: 10 mg/kg	
	cation Route	: Oral	
	sure time et Organs	: 14 - 104 We : Liver, Testis	
Speci	es	: Rabbit	
NOAE	EL	: 30 mg/kg	
LOAE		: 50 mg/kg	
	cation Route et Organs	: Oral : Liver, Kidne	
	at Lurrane		V

according to the Hazardous Products Regulations



ersion 2	Revision Date: 04/06/2024	SDS Numbe 24354-00023	
Starc	h:		
	EL cation Route sure time	: Rat : >= 2,000 : Skin con : 28 Days : OECD To	
Cellu	lose:		
		: Rat : >= 9,000 : Ingestion : 90 Days	
Asco	rbic acid:		
		: Rat, male : >= 8,100 : Ingestion : 13 Week	mg/kg
Citric	acid monohydrate:		
	ΞL	: Rat : 4,000 mg : 8,000 mg : Ingestion : 10 Days	/kg
Titan	ium dioxide:		
		: Rat : 24,000 m : Ingestion : 28 Days	
		: Rat : 10 mg/m : inhalation : 2 y	a n (dust/mist/fume)
-	ration toxicity lassified based on av	ailable informatio	n.
	rience with human e		
<u>Com</u>	ponents:		
	astatin: contact tion	: Target O Sympton dominal	: May produce an allergic reaction. rgans: Liver is: upper respiratory tract infection, Headache, Ab- pain, constipation, Nausea rgans: Musculo-skeletal system

according to the Hazardous Products Regulations



/ersion 7.2	Revision Date: 04/06/2024	-	0S Number: 354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014
SECTION	12. ECOLOGICAL INFO	ORN	IATION	
Foot	vicity			
	oxicity			
	ponents:			
-	astatin:			
IOXIC	ity to fish	:	Exposure time: 9	es promelas (fathead minnow)): 2.91 mg/l 96 h Fest Guideline 203
	ity to daphnia and other tic invertebrates	:	EC50 (Daphnia r Exposure time: 4	nagna (Water flea)): 3.5 mg/l 8 h
uquu				Fest Guideline 202
Toxici plants	ity to algae/aquatic S	:	EC50 (Pseudokin mg/l Exposure time: 9	rchneriella subcapitata (green algae)): > 25 96 h
			NOEC (Pseudok mg/l Exposure time: 9	irchneriella subcapitata (green algae)): 25
- .				
IOXIC	ity to microorganisms	:	EC50: > 30 mg/l Exposure time: 3 Test Type: Resp Method: OECD 7	
			NOEC: 21 mg/l Exposure time: 3 Test Type: Resp Method: OECD 1	
Cellu	lose:			
Toxic	ity to fish	:	Exposure time: 4	tipes (Japanese medaka)): > 100 mg/l 8 h on data from similar materials
Asco	rbic acid:			
Toxic	ity to fish	:	Exposure time: 9	chus mykiss (rainbow trout)): 1,020 mg/l 16 h Fest Guideline 203
Toxic	ity to microorganisms	:	EC50: 140 mg/l Exposure time: 1 Method: DIN 38	
Citric	acid monohydrate:			
	ity to fish	:	LC50 (Pimephale Exposure time: 9	es promelas (fathead minnow)): > 100 mg/l 96 h

according to the Hazardous Products Regulations



Version 7.2	Revision Date: 04/06/2024		0S Number: 354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014
	Toxicity to daphnia and other aquatic invertebrates		EC50 (Daphnia m Exposure time: 24	
Titan	ium dioxide:			
Toxic	Toxicity to fish		LC50 (Oncorhync Exposure time: 90 Method: OECD T	
	ity to daphnia and other tic invertebrates	:	EC50 (Daphnia m Exposure time: 48	nagna (Water flea)): > 100 mg/l 3 h
Toxic plants	ity to algae/aquatic s	:	EC50 (Skeletone Exposure time: 72	ma costatum (marine diatom)): > 10,000 mg/l 2 h
Toxic	ity to microorganisms	:	EC50: > 1,000 mg Exposure time: 3 Method: OECD T	ĥ
Persi	stence and degradabil	ity		
Com	ponents:			
Simv	astatin:			
Biode	egradability	:	Result: rapidly de	gradable
Stabi	lity in water	:	Hydrolysis: 50 %(3.2 d)
Cellu	lose:			
Biode	egradability	:	Result: Readily bi	odegradable.
Asco	orbic acid:			
Biode	egradability	:	Result: Readily bi Biodegradation: Exposure time: 5 Method: OECD T	97 % d
	c acid monohydrate: egradability	:	Result: Readily bi Biodegradation: Exposure time: 24 Method: OECD T	97 %
Bioa	ccumulative potential			
Com	ponents:			
Partit	a statin: ion coefficient: n- iol/water	:	log Pow: > 4.07	
Asco	rbic acid:			
			17 / 20	

according to the Hazardous Products Regulations



Simvastatin Formulation

Version 7.2	Revision Date: 04/06/2024	SDS Number: 24354-00023	Date of last issue: 09/26/2023 Date of first issue: 10/21/2014	
	ion coefficient: n- nol/water	: log Pow: -1.85		
Partit	c acid monohydrate: ion coefficient: n- nol/water	: log Pow: -1.72		
	lity in soil ata available			
••	r adverse effects ata available			

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods		
Waste from residues	:	Do not dispose of waste into sewer.
		Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:					
AICS	:	not determined			
DSL	:	not determined			
IECSC	:	not determined			

according to the Hazardous Products Regulations



Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/26/2023
7.2	04/06/2024	24354-00023	Date of first issue: 10/21/2014

SECTION 16. OTHER INFORMATION

Full text of other abbreviations					
ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)			
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)			
CA BC OEL	:	Canada. British Columbia OEL			
CA QC OEL	:	Québec. Regulation respecting occupational health and safe- ty, Schedule 1, Part 1: Permissible exposure values for air- borne contaminants			
ACGIH / TWA	:	8-hour, time-weighted average			
CA AB OEL / TWA	:	8-hour Occupational exposure limit			
CA BC OEL / TWA		8-hour time weighted average			
CA QC OEL / TWAEV	:	Time-weighted average exposure value			

AIIC - Australian Inventory of Industrial Chemicals: ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention: PBT - Persistent, Bioaccumulative and Toxic substance: PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to : compile the Material Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/



Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/26/2023
7.2	04/06/2024	24354-00023	Date of first issue: 10/21/2014
Revision Date Date format		: 04/06/2024 : mm/dd/yyyy	

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8